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Essentials
• Tumor-bearing mice were employed to follow oncogenic HRAS sequences in plasma, and blood cells.
• Cancer DNA accumulated in leukocytes above levels detected in exosomes, platelets and plasma.
• Extracellular vesicles and nucleosomes are required for uptake of tumor DNA by leukocytes.
• Uptake of tumor-derived extracellular vesicles by leukocytes triggers coagulant phenotype.
Summary. Background: Tumor-derived extracellular vesicles (EVs) and free nucleosomes (NSs) carry into the circulation a wealth of cancer-specific, bioactive and poorly understood molecular cargoes, including genomic DNA (gDNA). Objective: Here we investigated the distribution of extracellular oncogenic gDNA sequences (HRAS and HER2) in the circulation of tumor-bearing mice. Methods and Results: Surprisingly, circulating leukocytes (WBCs), especially neutrophils, contained the highest levels of mutant gDNA, which exceeded the amount of this material recovered from soluble fractions of plasma, circulating EVs, platelets, red blood cells (RBCs) and peripheral organs, as quantified by digital droplet PCR (ddPCR). Tumor excision resulted in disappearance of the WBCassociated gDNA signal within 2-9 days, which is in line with the expected half-life of these cells. EVs and nucleosomes were essential for the uptake of tumorderived extracellular DNA by neutrophil-like cells and impacted their phenotype. Indeed, the exposure of granulocytic HL-60 cells to EVs from HRAS-driven cancer cells resulted in a selective increase in tissue factor (TF) procoagulant activity and interleukin 8 (IL-8) production. The levels of circulating thrombin-antithrombin complexes (TAT) were markedly elevated in mice harboring HRAS-driven xenografts. Conclusions: Myeloid cells may represent a hitherto unrecognized reservoir of cancer
Introduction
The ability of tumor cells to release macromoleculecontaining particles into the circulating blood and biofluids has emerged as a unique mechanism of intercellular communication and biological regulation and a source of biomarkers in cancer [1] [2] [3] . In this regard the role of circulating extracellular vesicles (EVs) has long attracted experimental attention, as a possible mechanism of cancerassociated thrombosis (CAT) [4] . In addition, circulating tumor-related nucleosomes (NSs) have emerged as a source of cancer biomarkers [5] and as biological effectors [6] . Indeed, multiple studies highlighted the ability of circulating EVs to carry tissue factor (TF) and other coagulants and contribute to clot formation [2, 4, [7] [8] [9] [10] [11] . Such EVs may not only directly facilitate the assembly of coagulant complexes on their surfaces, but also transfer TF between different cellular populations, including monocytes, platelets, cancer cells and endothelium, a process resulting in intercellular transmission of procoagulant properties [2, [11] [12] [13] . Because the EV content of individual coagulant proteins, such as TF, is not always predictive of impending thrombosis [14, 15] , additional or alternative mechanisms have been proposed as constituents of CAT, including the involvement of platelets, mucins, phospholipids, polyphosphates, and especially nucleosomal gDNA [4, 16, 17] . Extracellular chromatin in a form of neutrophil extracellular traps (NETs) and NSs has also been implicated in the activation of the coagulation system [17] .
Alterations in hemostatic activities are inherent to the cancer cell phenotype and driven by several facets of malignant transformation. This includes deregulated expression of coagulant proteins [18] , EV biogenesis [19] and cargo assembly [20] . For example, the expression of the human HRAS oncogene in non-tumorigenic intestinal epithelial cells (IEC-18) results in their tumorigenic conversion (RAS-3 cells) coupled with an increase in EV production rates and the emission of mutant gDNA into the culture supernatant [19, 20] . Oncogenic gDNA has also been detected in EVs circulating in the plasma of cancer patients [21, 22] and may contribute to the pool of circulating cell-free tumor DNA (ctDNA) under development as a biomarker platform [23] . Indeed, both EV-associated and NS-associated circulating tumor gDNA may act as both an effector mechanism and a possible biomarker of systemic pathology, including CAT [24] , but the distribution of this material amongst cellular and soluble blood compartments is poorly understood.
In order to explore how cancer-related release of gDNA intersects with CAT we tracked unique mutant sequences across the compartments of the circulating blood and tissues in tumor-bearing mice. Remarkably, tumor-related gDNA sequences accumulated predominantly in circulating neutrophils, with several-fold lower content in liquid plasma, circulating EVs, platelets, RBCs and perfused organs. EVs and NSs were required to deliver gDNA to leukocytes, as these cells failed to take up the equivalent amounts of free DNA. The uptake of cancer EVs increased the coagulant and inflammatory properties of myeloid cells in culture, including their TF activity and IL-8 production. We propose that the accumulation of gDNA within the circulating leukocytes may be exploited as a novel liquid biopsy platform, and we suggest that this process may also contribute to systemic changes in CAT.
Materials and methods

Cells culture conditions
RAS-3 cells derived from rat intestinal epithelium (IEC-18) and carrying the human V12 c-H-ras (V12HRAS) [25, 26] oncogene were cultured as described earlier [19, 20] . The human breast cancer cell line (BT474; from Dr. K. Rosen, Dalhousie, Nova Scotia, Canada) harboring endogenous amplification of the HER2 oncogene was maintained in Hybri-Care media, with 10 mM sodium bicarbonate and 10% FBS. Human monocyte-like cells (THP-1) were cultured as suspension in RPMI-1640 basal medium with 10% FBS. Human neutrophil-like cells (HL-60) were cultured as suspension in Iscove's Modified Dulbecco's Medium (IMDM) with 20% FBS.
Animal studies, data and statistical analysis
All animal experiments were conducted in agreement with the Animal Utilization Protocol, approved by the institutional Animal Care Committee. Subcutaneous and intrasplenic xenografts were generated as described earlier [26, 27] . Briefly, for thrombin-antithrombin (TAT) ELISA, 5 9 10 5 RAS-3 cells in 40 lL DMEM were injected into the spleen of Fox Chase severe combined immune deficient (SCID) mice, followed by splenectomy after 5 min of injection. For this purpose, the surgical field was antiseptically prepared and the spleen was accessed and exteriorized through lateral laparotomy under isoflurane anesthesia. After cell injection splenic vessels were ligated and the spleen resected while maintaining surgical hemostasis, followed by suture of the peritoneum, abdominal wall and skin. In this model macroscopic liver metastases are observed within 2 weeks of injection and prior to the onset of any clinical symptoms. On day 13, mice were subjected to laparotomy to validate the occurrence of liver nodules, after which blood was collected from tumor-bearing and tumor-free mice via the inferior vena cava (IVC) using 3.8% sodium citrate as anticoagulant. Plasma was prepared from blood samples ( Figure S3 ) and analyzed by ELISA (Assaypro, St Charles, MO, USA; catalog No. EMT1020-1) prior to humane sacrifice of the mice. All data were independently reproduced at least two to three times and statistically analyzed using a two-tailed t-test with the P-value threshold of 0.05. Additional results and experimental details are included in the supplementary figures ( Figure S1 to Figure S25 ).
Results
Cancer cell-derived extracellular vesicles and nucleosomes contain mutant gDNA
We have previously reported that transformation of rat epithelial cells (IEC-18) with oncogenic human HRAS (RAS-3 cells) leads to dramatic changes in cellular phenotype, tumorigenicity and enhanced vesiculation, including EV-mediated emission of mutant genomic DNA (gDNA) [19, 20] . RAS-3 cells release EVs with sizes and morphologies consistent with those of exosomes, as observed by transmission electron microscopy (TEM) (Fig. 1A) [19, [28] [29] [30] . Both EVs and non-EV chromatin (NSs) can be isolated from media conditioned in the presence of RAS-3 cells ( Figure S1 ) and serve as sources of extracellular gDNA and mutant HRAS sequences, as shown by the bioanalyzer and PCR analysis, respectively (Fig. 1B-C) .
Detection of oncogenic gDNA in circulating leukocytes of tumor-bearing mice RAS-3 (but not IEC-18) [26] cells are highly tumorigenic, and their ability to shed gDNA into the bloodstream would be of interest as a model of ctDNA release in vivo.
To explore this notion we used standard PCR and digital droplet PCR (ddPCR) [31] to assay for the content of mutant HRAS gDNA in soluble and cellular fractions of the circulating blood and in selected tissue compartments of mice harboring RAS-3 xenografts ( Figure S2 ). We isolated the soluble fraction of plasma ctDNA, plasma EVs, platelets, and white as well as red blood cells (WBCs and RBCs) ( Figure S3 ), along with samples of solid tissues enriched for myeloid and phagocytic cells, including liver, spleen and bone marrow ( Fig. 2 and 3A ,B). It is noteworthy that in this setting the exogenously expressed human oncogenic (mutant) HRAS gene can be unambiguously distinguished from the endogenous cellular gDNA (rat) of RAS-3 cancer cells, and from the host (mouse) gDNA.
Notably, both standard PCR (Fig. 2 ) and quantitative ddPCR analysis (Fig. 3A,B) revealed that all fractions of circulating blood and tissues contained some amounts of the oncogenic HRAS DNA, suggesting that cancer cellderived material is widely and systemically distributed in tumor-bearing mice. However, the levels of HRAS gDNA in different compartments were markedly different.
Strikingly, in spite of EVs acting as a major exit portal for extracellular gDNA [19] , the greatest and most consistent accumulation of this material was detected in circulating WBCs and not in plasma (ctDNA) or plasma-derived EVs. In particular, the HRAS gDNA levels in EVs were exceedingly low in at least two/five mice despite comparable tumor burden across the cohort, and only one/five mice contained a detectable HRAS signal in the RBC fraction, in spite of its abundance. The HRAS signal was also low in two/five spleen samples, but more apparent in the bone marrow (Fig. 2) .
We also analyzed separate sample sets using the quantitative ddPCR assay ( Figure S4 ). In this case, the numbers and distribution of circulating copies of HRAS gDNA were quantified and compared between different fractions isolated from the same volume of blood (e.g. ctDNA, EVs, platelets, WBCs and RBCs; Fig. 3A ). Once again, the HRAS gDNA content in the WBC fraction exceeded by a 2-3-fold that of all the remaining blood fractions. This signal was also enriched in WBCs in comparison to lysates of the bone marrow, spleen and liver from the same mice, relative to the endogenous (mouse) gDNA controls (b-actin; Fig 3B) , even though these organs are highly cellular and are viewed as sites of systemic EV retention [29, 32] . These observations suggest that WBCs may represent an enriched reservoir of oncogenic gDNA emitted from cancer cells into the circulation.
Leukocyte content of oncogenic gDNA depends on the presence of the tumor burden
To assess the scope and dynamic capture of oncogenic gDNA by the circulating WBCs, we collected serial tail bleeds from mice harboring RAS-3 xenografts before and after surgical tumor removal ( Figure S5 ). Samples of 100 lL of blood were collected on indicated days and due to volume limitation were subjected to simplified fractionation into serum (ctDNA and EVs) and cellular (WBC) compartments. Once again, we observed that the mutant HRAS gDNA was primarily associated with the cellular fraction of blood and barely detectable in the serum. The blood cell (WBC)-associated gDNA signal declined from high to undetectable over 9 days post-surgery, during which time the serum levels of HRAS DNA remained consistently low (Fig. 3C ). These observations highlight the presence of the tumor burden as the source of the WBCassociated gDNA signal, the decline of which after surgery reflects the expected half-life of circulating leukocytes [33] . It is also noteworthy that in a small sample volume, blood cells (WBCs) are the only fraction of blood in which oncogenic sequences are consistently detectable in this model.
Finally, we examined the content of human HER2 DNA in blood compartments of mice harboring human BT474 breast cancer xenografts ( Figure S2-S4 ). These tumors are driven by the amplification of the HER2 oncogene and release the corresponding gDNA into the extracellular space. Also in this model, with vastly different genetic and biological characteristics, the highest and most consistent levels of HER2 DNA were detected in the WBC fraction, to a degree significantly greater than that of circulating EVs and platelets, and far exceeding the signal from ctDNA dissolved in plasma (Fig. 3D ). We also tested circulating HER2 gDNA in blood compartments of mice harboring human patient-derived xenografts of gastric cancer with HER2 amplification. Although there was some variability in results obtained with this less-standardized model, the most consistent HER2 gDNA signal was obtained from the WBC fraction of blood ( Figure S6 ). Collectively, these observations suggest that the WBC fraction of blood may represent an unsuspected and highly enriched reservoir of tumor-derived signature DNA, the impact of which on the biology of blood, including hemostasis, has not been investigated.
Oncogenic gDNA in the WBC fraction of blood is unrelated to circulating cancer cells (CTCs) We considered the possibility that high content of mutant HRAS gDNA in the WBC fraction could represent a contamination of blood with CTCs. However, we detected were isolated using ultracentrifugation and the EV pellets were processed and imaged using transmission electron microscopy to reveal exosome-like morphology. (B-C) DNA was isolated from RAS-3 EV pellets and supernatant (free DNA, including nucleosomes -NSs) and the material was analyzed using bioanalyzer and PCR methods. NTC, no template control. [Color figure can be viewed at wileyonlinelibrary.com] up to 80 000 copies of the mutant HRAS sequence per 100 lL of blood, which would correspond to thousands of CTCs, far in excess of what is expected in clinical or experimental cancer settings [34] . Moreover, we performed fluorescence activated cell sorting (FACS) analysis on blood samples collected from mice harboring mCherry labeled RAS-3 ( Figure S7 ) tumors. These assays showed no readily detectable mCherry fluorescence in the WBC population of circulating blood cells (Fig. 4A-C) . In addition, the culture of blood ( Figure S8 ) from tumorbearing mice resulted in no detection of G418-resistant tumor cell colonies for over a 90-day period. This is a very sensitive criterion as plating as few as 20 individual RAS-3 cells results in the formation of five colonies that expand to confluent cultures within 25 days (Fig. 4D-F) . Thus, we concluded that in this model CTCs are not a detectable source of circulating tumor-related gDNA associated with the WBC compartment of blood.
Accumulation of tumor-related gDNA in circulating neutrophils
To address which of the WBC subpopulations carry tumor-related gDNA, buffy coat cell isolates were labeled with antibodies (Abs) against Ly6G and Ly6C antigens and sorted to isolate fractions enriched for granulocytes (Ly6G+/Ly6C+), monocytes (Ly6GÀ/Ly6C+) and lymphocytes (Ly6GÀ/Ly6CÀ) ( Figure S9 ), with additional verification utilizing forward versus side scatter (SSC/ FSC) profiles. The respective WBC subpopulations were subsequently assayed for human HRAS gDNA using ddPCR ( Fig. 5A-B ). This analysis identified neutrophils as a major reservoir of HRAS sequences per 1 ml of blood volume ( Figure S10 ), whereas monocytes and lymphocytes carried markedly less of this material (Fig. 5B ). Of note, the HRAS gDNA content per cell was high in both neutrophils and monocytes, but the former cells were more prominent numerically ( Figure S11 ). Indeed, when neutrophils were depleted in RAS-3 tumorbearing mice using the anti-Ly6G Ab (Fig. 6A, S10 ) the amount of cell-free gDNA significantly increased in the circulation, including both ctDNA (NSs) and EV fractions. This observation may suggest that neutropenia caused by chemotherapy and other factors could lead to a redistribution of the oncogenic gDNA signal among blood compartments (Fig. 6B,C) .
Myeloid cells selectively uptake gDNA associated with extracellular vesicles and nucleosomes
Although EVs act as portals for the gDNA exit from cancer cells their role in transmission of this material to circulating myeloid cells has not been fully examined. To assess whether EVs are required to efficiently deliver extracellular gDNA to WBCs, we used cultured human neutrophil-like (HL-60) and monocyte-like (THP-1) cell lines to first examine their ability to uptake RAS-3-derived EVs labeled with PKH26 red fluorescent dye (Figure S12) . Indeed, FACS and confocal imaging revealed the avid uptake of EVs by both cell lines ( Fig. 7A,B; Figure S13A,B) . Furthermore, HL-60 and THP-1 cells incubated with RAS-3-derived EVs retained readily detectable amounts of cancer cell-related (rat) gDNA for at least 10 days, as indicated by PCR analysis of their content of rat b-actin ( Figure S14 and S15) and in keeping with earlier reports [19] . In contrast, equivalent or greater amounts of free gDNA (purified from RAS-3 EVs) were not taken up by . Samples were used to PCR amplify human-specific HRAS oncogene sequences and the amplicons generated were loaded onto 2% agarose gel. The signal was compared between severe combined immune deficient (SCID) mice harboring RAS-3 tumor xenografts with indicated volumes (% maximal, all tumors were > 1 g).
these cells ( Fig. 7C ; Figure S13C ). Because RAS-3 cells also emit certain amounts of extracellular gDNA that is not contained in EVs (Fig. 1C ) and is associated with NSs (Figures S14 and S16; data not shown), we incubated HL-60 cells with this material. Like EVs, also NSs were involved in, and required for, the uptake of gDNA by HL-60 cells, which were unable to internalize the equivalent quantities of free gDNA (isolated from NSs, Fig. 7D ). In this case, the integrity of nucleosomes and free DNA was confirmed using DNA-histone sandwich ELISA (Fig. 7E) . Taken together these observations indicate that EVs and NSs (the main components of the ctDNA fraction in plasma) deliver the circulating cancer cell-related gDNA to myeloid phagocytes for sequestration.
Tumor-derived vesicles selectively upregulate IL-8 in the recipient myeloid model
To examine whether the uptake and retention of cancer-derived EVs containing gDNA has a functional impact on recipient cells we incubated HL-60 cells with Figure S17-19 ). First, we used an array containing 36 immobilized antibodies against human cytokines and chemokines, which revealed a detectable upregulation of IL-8 in HL-60 cells stimulated with RAS-3 EVs. Other cytokines were negligibly affected by RAS-3 EVs, except for some increases in CXCL12/SDF-1 and macrophage migration inhibitory factor. These effects were considerably more selective than those of lipolysaccharide (LPS) (Figure S18-19) . The preferential impact of RAS-3 EVs on IL-8 secretion by HL-60 cells was further confirmed using ELISA, which also documented a much weaker effect of IEC-18 EVs ( Fig. 8A ; Figure S17 ; Figure S18-19 ). These observations suggest that myeloid cells are not only carriers, but also regulatory targets of cancerderived EVs [35] .
EVs from either normal (IEC-18) or HRAS-transformed (RAS-3) cells and examined their cytokine and chemokine expression profiles (
Uptake of cancer-derived EVs stimulates tissue factor procoagulant activity in leukocytes
Activation of myeloid cells is among important constituents of CAT [36, 37] , and may involve the expression and/or decryption of TF by neutrophils [38] . To explore whether cancer-derived EVs may contribute to these effects, we analyzed TF antigen expression and procoagulant activity (TF-PCA) of HL-60 cells treated with RAS-3-derived or IEC-18-derived EVs for 24 h ( Fig. 8B ; Figure S21 ). The addition of factor (F) VIIa to EV-treated cells leads to formation of TF/VIIa complexes on the cell surface, resulting in the activation of exogenous FX (to Xa) that can be measured as TF-PCA using a colorimetric assay [39] . Under these conditions, neither EV preparation induced a major change in HL-60 cell proliferation and survival ( Figure S22 ). Interestingly, although the global level of TF on the surface of HL-60 cells remained largely unchanged regardless of treatment (Figure S23) , the TF-PCA output was markedly and selectively increased upon the exposure to EVs from RAS-3 cells. EVs released from IEC-18 cells lacked this activity (Fig. 8B ). In keeping with this observation, levels of thrombin-antithrombin complexes (TATs) ( Figure S24 ) in mice harboring metastatic RAS-3 xenografts were markedly elevated, indicating activation of the coagulation cascade in vivo (Fig. 8C) . In order to explore whether cancer EVs also influence TF signaling we pretreated HL-60 cells with RAS-3-derived or IEC-18-derived EVs and assayed the cellular responses to recombinant FVIIa by measuring IL-8 release ( Figure S17 ). As shown in Fig. 8(D) , FVIIa triggered some IL-8 production under all experimental conditions, but the exposure to EVs had a far greater impact, especially in the case of EVs derived from RAS-3 cells. The combined effect of VIIa and EV treatment was only marginally greater than the effects of RAS-3-derived EVs alone. RAS-3 EVs did not stimulate increases in TF or IL-8 mRNA. They also did not trigger interferon alpha (IFNa) or endoplasmic reticulum (ER) stress proteins (GRP78) [40] in recipient cells ( Figures S20 and S25) , suggesting mechanisms of stimulation other than gene transcription, foreign DNA or protein overload [41] . Thus, TF-PCA induced by exposure to RAS-3-derived EVs is indicative of TF activation (decryption) and, as expected, does not lead to enhanced TF signaling [42] .
Discussion
Our study explores a nexus between the role of EVs as carriers of the cancer-related oncogenic gDNA ('liquid biopsy') in the circulation and their interactions with host cells, with consequences for the coagulation system. In this regard we report several novel observations. First, both EVs and NSs represent portals for extracellular gDNA exit from cancer cells and the entry point of this material into circulating leukocytes, especially neutrophils. Both EVs and NSs mediate the uptake of cancer-related gDNA by neutrophils, which represent the hitherto unsuspected major reservoir of this material in the circulating blood. Thus, circulating neutrophils can be regarded as a possible novel and enriched platform for 'liquid biopsy' to retrieve potentially diagnostic mutations (e.g. V12HRAS) from blood samples in cancer. Second, our study demonstrates functional consequences of myeloid cell interactions with cancer-related EVs in vitro and in vivo, resulting in a more proinflammatory and procoagulant phenotype. This is illustrated by an EV-mediated increase in IL-8 production and TF activation by neutrophils, and the elevated TATs in xenograft-bearing mice. We posit that the states of myeloid cells during pathophysiological responses to cancer, such as inflammation, neutropenia, neutrophilia or thrombosis, should be (and rarely are) considered as modulators of liquid biopsy options. Indeed, there is an intense interest in the recovery and analysis of diagnostically and therapeutically informative gDNA sequences from blood samples, including CTCs and ctDNA (circulating NSs), with more recent explorations encompassing platelets [43] and EVs/exosomes [23] . Our findings suggest a novel role for EVs and NSs in the flux of extracellular gDNA from cancer cells to cellular compartments of blood and tissues. Indeed, given the relatively low volume of neutrophils and monocytes in blood among other blood compartments (1%) [43] , their strong and consistent content of cancer-related DNA (40-60% of HRAS copies) may suggest their unique sequestration of this material. Thus, choices of liquid biopsy options should be guided by biological and not only technical considerations.
Although cancer EVs may serve as carriers of diagnostic gDNA, they also possess important biological functions in cellular regulation [20] , angiogenesis [1] , immunoregulation [44] and thrombosis [4] . At least some of these activities may involve circulating myeloid cells, as documented in studies on the role of EVs in formation of the pre-metastatic niche [35] and the intercellular transfer of TF [12, 45] . Interestingly, a recent study by Leal et al. [46] documented induction of NETs by cancer-derived small EVs (exosomes) and the role of the resulting extracellular DNA in thrombosis. Our study proposes another mechanism by which exosome-like EVs could trigger coagulant responses in myeloid cells without NET formation, namely by activation of TF procoagulant activity.
The mechanism by which cancer-related EVs trigger an increase in TF-PCA of HL-60 cells is presently unknown and requires further study, including additional models of neutrophils amenable to mechanistic explorations. Although both TF-PCA induction and gDNA content separate EVs from HRAS-driven cancer cells from those of their untransformed isogenic counterparts, the link between these properties is uncertain. In addition to gDNA, RAS-3-derived EVs carry diverse molecular cargoes (data not shown) with potential relevance to their biological activity [20] . Moreover, our prior study [19] suggests that gDNA is located within the RAS-3 EV lumen and the uptake of these EVs directs them into the cytoplasm of recipient leukocytes, thereby rendering their nucleic acid cargo inaccessible to the coagulation system. Although other studies suggested a role of phospholipid HRAS signal in different fractions of blood as measured by digital droplet PCR (ddPCR). **Pvalue = 0.007, ***P-value < 0.001. (C) Mice treated with anti-Ly6G: changes in HRAS signal in various blood fractions upon neutrophil depletion; *P-value = 0.01, **P-value = 0.0012, ***P-value < 0.0001, ns = not significant.
and other EV surface components in their coagulant activities [4] , those mechanisms would be difficult to reconcile with internalization of EVs in our model (probably phagocytosis or macropinocytosis) [20] . Although TF activation could be triggered from within by ER stress and other responses [40] , this scenario is not borne out in our data and the related mechanisms remain to be investigated. Oncogenic RAS and other transforming events simultaneously trigger several interconnected processes that influence systemic manifestations of cancer, including the angiogenic, inflammatory and coagulant phenotypes of cancer and host cells [18, 47, 48] . These processes may increase the clinical risk of thrombosis [49] and modulate vesiculation processes [19] , including EV-dependent and independent emission of coagulant activities and gDNA [18, 20] . Our study reveals new linkages between these processes and a role of neutrophils as their harbingers.
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